Herren Wu
50Patents
20h-index
48Co-inventors
88Inventor score
Filing activity: Feb 10, 1999 → May 4, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8409568B2 | Mutant antibody Fc domains and fusion proteins thereof | Chemistry; Metallurgy | 85 | Active |
| US8309690B2 | Integrated approach for generating multidomain protein therapeutics | Chemistry; Metallurgy | 82 | Active |
| US7658921B2 | Molecules with extended half-lives, compositions and uses thereof | Chemistry; Metallurgy | 56 | Active |
| US6656467B2 | Ultra high affinity neutralizing antibodies | Chemistry; Metallurgy | 52 | Expired |
| US7229619B1 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 46 | Expired |
| US6531580B1 | Anti-&agr;v&bgr;3 recombinant human antibodies and nucleic acids encoding same | Chemistry; Metallurgy | 42 | Expired |
| US6312693A | Antibodies against human CD40 | Chemistry; Metallurgy | 36 | Expired |
| US7323172B2 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 33 | Expired |
| US7354584B2 | Recombinant IL-9 antibodies | Chemistry; Metallurgy | 32 | Expired |
| US7553489B2 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 32 | Active |
| US7531169B2 | High affinity anti-human IgE antibodies | Emerging Cross-Sectional Technologies | 31 | Expired |
| US7179900B2 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 31 | Expired |
| US7790655B2 | Cell display of antibody libraries | Chemistry; Metallurgy | 28 | Active |
| US8252284B2 | High affinity, anti-human IgE antibodies | Emerging Cross-Sectional Technologies | 27 | Active |
| US7635568B2 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 26 | Expired |
| US8604171B2 | High affinity, anti-human IgE antibodies | Emerging Cross-Sectional Technologies | 26 | Active |
| US7740851B2 | Ultra high affinity neutralizing antibodies | Chemistry; Metallurgy | 25 | Active |
| US8008443B2 | Modulation of antibody effector function by hinge domain engineering | Chemistry; Metallurgy | 24 | Active |
| US7847082B2 | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment | Chemistry; Metallurgy | 23 | Active |
| US8323653B2 | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease | Emerging Cross-Sectional Technologies | 22 | Active |
| US8067002B2 | Humanized anti-factor D antibodies | Chemistry; Metallurgy | 19 | Active |
| US8153133B2 | High potency recombinant antibodies and method for producing them | Chemistry; Metallurgy | 19 | Active |
| US7585504B2 | High affinity antibodies against HMGB1 and methods of use thereof | Emerging Cross-Sectional Technologies | 16 | Active |
| US8697396B2 | Modulation of antibody effector function by hinge domain engineering | Chemistry; Metallurgy | 15 | Active |
| US7659374B2 | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity | Physics | 14 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.